903 results on '"Krämer, Alwin"'
Search Results
2. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
3. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
4. CUP-Syndrom – die neue ESMO-Leitlinie
5. Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich
6. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
7. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
8. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
9. Synthetic patches, real images: screening for centrosome aberrations in EM images of human cancer cells
10. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
11. Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie
12. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
13. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
14. Human SLFN5 and its Xenopus Laevis ortholog regulate entry into mitosis and oocyte meiotic resumption
15. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
16. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
17. Prediction of acute myeloid leukaemia risk in healthy individuals.
18. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
19. Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary
20. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
21. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
22. Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
23. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
24. Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells
25. Management of a pregnant ALK-positive lung cancer patient with alectinib-induced pneumonitis and bilateral globus pallidus necrosis postpartum
26. CUP-Syndrom – Tumorerkrankung mit unbekanntem Primärtumor
27. The clinical mutatome of core binding factor leukemia
28. TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia
29. Enasidenib
30. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
31. Diagnostic Work-up of CUP: An Approach to Current Recommendations and Underlying Evidence
32. Future Directions
33. Prognostic Factors and Their Role in the Management of CUP
34. Biologic Features of CUP
35. Introduction
36. Cancer of unknown primary—The new ESMO guidelines
37. 2. Diagnose und WHO-Klassifikation myeloischer Neoplasien
38. SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia
39. Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
40. Data from HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
41. Supplementary Data from HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
42. Supplementary data from Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization
43. Supplementary movie S2 from Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization
44. Supplementary Table S1 from Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization
45. Supplementary Video 1 from Cep63 Recruits Cdk1 to the Centrosome: Implications for Regulation of Mitotic Entry, Centrosome Amplification, and Genome Maintenance
46. Supplementary Figure 4 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo
47. Supplementary Video 2 from Cep63 Recruits Cdk1 to the Centrosome: Implications for Regulation of Mitotic Entry, Centrosome Amplification, and Genome Maintenance
48. Data from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo
49. Supplementary Figure 1 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo
50. Supplementary Figure 3 from Identification of Griseofulvin as an Inhibitor of Centrosomal Clustering in a Phenotype-Based Screen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.